122 related articles for article (PubMed ID: 31478753)
1. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
[No Abstract] [Full Text] [Related]
2. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
[TBL] [Abstract][Full Text] [Related]
3. Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant.
Kale HP; Qureshi ZP; Shah R; Khandker R; Botteman M; Meng W; Benca R
Adv Ther; 2021 Oct; 38(10):5221-5237. PubMed ID: 34463922
[TBL] [Abstract][Full Text] [Related]
4. Preventive Effects of Ramelteon, Suvorexant, and Lemborexant on Delirium in Hospitalized Patients With Physical Disease: A Retrospective Cohort Study.
Henmi R; Nakamura T; Mashimoto M; Takase F; Ozone M
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):369-377. PubMed ID: 38820374
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.
Ozone M; Hirota S; Ariyoshi Y; Hayashida K; Ikegami A; Habukawa M; Ohshima H; Harada D; Hiejima H; Kotorii N; Murotani K; Taninaga T; Uchimura N
Adv Ther; 2024 Apr; 41(4):1728-1745. PubMed ID: 38460107
[TBL] [Abstract][Full Text] [Related]
6. New insights on the potential effect of orexin receptor antagonist suvorexant on Parkinson's disease symptoms.
Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Saad HM; Batiha GE
Neurol Sci; 2024 May; 45(5):2367-2368. PubMed ID: 38231375
[No Abstract] [Full Text] [Related]
7. Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study.
Ishibashi Y; Nishitani R; Shimura A; Takeuchi A; Touko M; Kato T; Chiba S; Ashidate K; Ishiwata N; Ichijo T; Sasabe M
PLoS One; 2020; 15(9):e0238723. PubMed ID: 32916693
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis.
Na HJ; Jeon N; Staatz CE; Han N; Baek IH
Sleep; 2024 Feb; 47(2):. PubMed ID: 37950346
[TBL] [Abstract][Full Text] [Related]
9. New Developments in Insomnia Medications of Relevance to Mental Health Disorders.
Krystal AD
Psychiatr Clin North Am; 2015 Dec; 38(4):843-60. PubMed ID: 26600112
[TBL] [Abstract][Full Text] [Related]
10. Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study.
Fernandes M; Placidi F; Mercuri NB; Liguori C
Neurol Sci; 2024 Jul; 45(7):3443-3448. PubMed ID: 38280086
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of suvorexant and lemborexant for insomnia treatment.
Hayashi T; Yamanashi T; Iwata M
PCN Rep; 2023 Mar; 2(1):e85. PubMed ID: 38868407
[TBL] [Abstract][Full Text] [Related]
12. The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report.
Campbell EJ; Bonomo Y; Collins L; Norman A; O'Neill H; Streitberg A; Galloway K; Kyoong A; Perkins A; Pastor A; Lawrence AJ
Clin Case Rep; 2024 May; 12(5):e8740. PubMed ID: 38698873
[TBL] [Abstract][Full Text] [Related]
13. Is schedule IV suvorexant an appropriate reference drug of abuse to use in preclinical abuse liability testing in the rat?
Teuns GBA; Tessari M
Regul Toxicol Pharmacol; 2024 Mar; 148():105570. PubMed ID: 38286304
[TBL] [Abstract][Full Text] [Related]
14. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts.
Uslaner JM; Herring WJ; Coleman PJ
ACS Pharmacol Transl Sci; 2020 Feb; 3(1):161-168. PubMed ID: 32259095
[TBL] [Abstract][Full Text] [Related]
15. Correction to "The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report".
Clin Case Rep; 2024 Jun; 12(6):e8961. PubMed ID: 38799523
[TBL] [Abstract][Full Text] [Related]
16. Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis.
Kishi T; Nomura I; Matsuda Y; Sakuma K; Okuya M; Ikuta T; Iwata N
J Psychiatr Res; 2020 Sep; 128():68-74. PubMed ID: 32531478
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review.
Sys J; Van Cleynenbreugel S; Deschodt M; Van der Linden L; Tournoy J
Eur J Clin Pharmacol; 2020 Mar; 76(3):363-381. PubMed ID: 31838549
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
